ConcertAI, a US-based company that deals with oncology predictive and generative AI SaaS Solutions and Real-World Data for healthcare and life sciences, announced on Monday that it has named Timothy (Tim) Albury as its new chief financial officer (CFO).
Albury, an accomplished finance executive, has served for 12 years at Arthur Andersen and around 25 years as CFO of various companies across multiple industry sectors. He has most recently served as CFO of AQuity Solutions. He was also a part of the leadership team growing KBI BioPharma, Osmotica Pharma, and Liquidia Corp (LQDA).
Albury said, 'ConcertAI is uniquely poised to expand its position as the clinical AI and Real-World Data leader. I am excited to join the talented ConcertAI team as the company enters a new phase of growth by bringing predictive and generative AI SaaS innovations to our customers in healthcare and clinical development.'
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration